Cardiac Glycoside Receptors and Positive Inotropy: Evidence for more than one receptor?

Front Matter....Pages 1-6
Cardiac glycoside receptors and positive inotropy Evidence for more than one receptor?....Pages 7-8
Theory of ligand — receptor interactions — Evidence for more than one site....Pages 9-15
Cardiac Glycosides and sodium/potassium-ATPase....Pages 16-20
Two receptors for cardiac glycosides in the heart....Pages 21-26
Subclassification of cardiac glycoside receptors....Pages 27-34
Cardiac glycoside binding sites in cultured heart muscle cells....Pages 35-43
Binding sites for ouabain in human and rat erythrocytes and in rat heart cells....Pages 44-49
Two binding sites for ouabain in cardiac cell membranes....Pages 50-55
Contractility of isolated bovine ventricular myocytes is enhanced by intracellular injection of cardioactive glycosides. Evidence for an intracellular mode of action....Pages 56-71
The electrogenic Na-K pump current and actions of the cardiac glycosides....Pages 72-78
Effects of non-toxic doses of ouabain on sodium, potassium, calcium distribution in guinea pig papillary muscle. Electronprobe microanalysis....Pages 79-86
Cardiac glycosides and intracellular Na + , K + , Ca 2+ ....Pages 87-92
Cardiac glycosides with different effects in the heart....Pages 93-101
Biphasic positive inotropic actions of ouabain on rat, guinea-pig and cat heart: a mathematical description....Pages 102-109
Digitalis receptors affinity labelling and relation with positive inotropic and cardiotoxic effects....Pages 110-118
Two ouabain binding sites in guinea pig heart Na + -K + - ATPase. Differentiation by sodium and erythrosin B....Pages 119-127
Effects of calcium on the heterogeneity of the Na + , K + -ATPase forms in rat heart....Pages 128-133
Positive inotropic effects of digitoxin- and digoxin-glucuronide in human isolated ventricular heart muscle preparations....Pages 134-139
Studies of the inotropic mechanisms of cardiac glycosides in cultured heart cells....Pages 140-146
Therapeutic range of cardiac glycosides....Pages 147-153
Increased therapeutic range, merely a pharmacokinetic problem?....Pages 154-160
Back Matter....Pages 161-162